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Abstract
Objective: To evaluate the effect of vaginal disinfection with chlorhexidine gel during labor on vertical transmission of group 
B streptococcus, as a method to prevent vertical transmission and subsequent neonatal early onset group B streptococcal disease. 
Study Design: A prospective study with randomization of 1020 parturients to one of three groups as soon as labor started. In all 
parturients, anus, introitus and cervix were cultured semiquantitatively. Two groups were treated double-blindly with 10 ml of 
either a 0.3% chlorhexidine gel or a placebo gel, applicated around the portio and into the fomices. If labor still continued, a second 
application was given after 10 h. The third group received no treatment. Ear, pharynx and umbilicus of all newborns were also 
cultured semiquantitatively. Results: Nine hundred and eighty one women were evaluated. The overall incidence of group B strep­
tococcal carriership was 19.4%. Vertical transmission was 52.4% in the chlorhexidine group, 71.4% in the placebo group and 66.7% 
in the control group (P = 0.069). When testing the transmission rates for the chlorhexidine versus the combined placebo plus control 
group (69.3%), the difference was 16.9% (P ~ 0.026). Conclusion: Vaginal disinfection with a chlorhexidine gel during labor modest­
ly reduces group B streptococcal vertical transmission. Because the method is cheap, simple and safe, it should be considered for 
routine use. Our results indicate that it may reduce the incidence of early onset group B streptococcal sepsis by 2-32%.
Keywords: Streptococcus agalactiae\ Primary prevention; Septicemia; Disinfection; Chlorhexidine
1. Introduction
Group B /3-hemolytic streptococcus (GBS, Strepto­
coccus agalactiae) is the leading cause of neonatal sepsis 
with eventual meningitis and accounts for 10-25% of 
postpartum maternal bacteremia [1,2]. Invasive neona­
tal GBS infections present themselves either as ‘early5 
(usually within 24 h) or ‘late onset* (7 days-3 months) 
disease. Early onset infections make up two thirds of 
cases and are usually acquired by vertical transmission
* Corresponding author, Tel.: +31 80 614725; Fax: +31 80 541194.
from the mother’s genital tract [1,2]. Asymptomatic ma­
ternal genital GBS colonization may be intermittent or 
temporary rather than permanent and occurs in 4-40%  
(usually about 20%)) of pregnant women, depending on 
the population studied and culture technique used 
[1-3]. The rectum serves as a reservoir for colonization 
of the vagina, and genital tract isolation rates are 
reported highest from the lower vagina (introitus) and 
lowest from the cervix [1,2]. In infants bom of GBS car­
riers, vertical transmission range from 40-70%, the 
higher percentage being associated with a high genital 
inoculum. Despite high prevalence rates for vertical
0301-2115/95/$09.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved 
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transmission, the incidence of early onset GBS infection 
is only 1-10/1000 live births. Albeit a small group, pre­
vention is important because of the high mortality rate: 
50-70% in older studies and 13-37% in more recent 
studies [1,2], Furthermore, about half of the infants sur­
viving GBS meningitis are left with permanent 
neurologic sequelae.
There is no consensus on the best approach to prevent 
early onset GBS infection [4]. It is important to recog­
nize perinatal risk factors, including low birthweight, 
preterm delivery, prolonged rupture of membranes, in­
trapartum fever and heavy maternal GBS colonization 
[1,2,5], Infants of mothers with low levels of serogroup- 
specific antibodies against GBS are at risk [1]. A pro­
gram of active immunization aimed at pregnant women 
or, alternatively, at all women in the childbearing years 
would probably be most efficient in controlling peri­
natal GBS disease. However, an effective vaccine is not 
yet available [6]. Antibiotic treatment during pregnancy 
is not adequate [7], neither can single-dose penicillin 
prophylaxis in infants be recommended [8]. Intrapartum 
prevention with antibiotic therapy (ampicillin, penicillin 
G) has been shown to reduce GBS vertical transmission 
[9-16]. Vaginal chlorhexidine disinfection during labor 
has been proposed as a simple, cheap and safe [17] alter­
native without risk for development of bacterial resis­
tance and only a very low risk for allergic complications 
[18-20]. It can be used not only in delivery wards but 
also in home deliveries and in the developing world. 
Chlorhexidine might also reduce the transmission of 
other potential pathogens. Moreover, as compared to 
antibiotic therapy, chlorhexidine disinfection would ob­
viate the necessity of selection. The omission of rapid 
GBS antigen tests would be advantageous as, so far, 
they lack sufficient sensitivity [21].
In 1992, chlorhexidine disinfection during labor was 
reported to reduce excess neonatal morbidity associated 
with GBS [22], However, the effect on vertical transmis­
sion was not investigated. Stimulated by the promising 
results of a small clinical pilot study [20], we in­
vestigated the effect of vaginal chlorhexidine gel dis­
infection on vertical transmission of GBS in a 
randomized trial.
2. Subjects and methods
2. L Subjects and design
The trial was conducted from February 1991 through 
November 1992 in the two hospitals with obstetric ser­
vices in the city of Nijmegen, The Netherlands. Eligible 
pregnant women received written information on the 
trial during pregnancy or at admission to the delivery 
ward. Exclusion criteria were: known GBS carriership 
(allowing responsible obstetricians to take different pre­
ventive measures), use of antibiotics during the 4 weeks
before admission, planned caesarean section, antepar­
tum fetal death, suspected congenital abnormalities and 
immature labor. The protocol was approved by the 
ethical committees of both institutions and written in­
formed consent was obtained from all parturients 
enrolled in the trial.
The goal of the trial was to study the effect of 
chlorhexidine disinfection on the rate of GBS transmis­
sion to the neonate. Secondary goals were to study the 
vertical transmission rates of Escherichia coli> 
Staphylococcus aureus and Candida albicans, and to es­
tablish neonatal and maternal morbidity.
Two groups were treated in a double-blind manner 
with either a chlorhexidine or a placebo gel. To detect 
any possible effect of treatment with placebo gel, a third 
group received no treatment at all. A pre-study calcula­
tion of the required sample size was performed, assum­
ing the prevalence of GBS among parturients to be 20%. 
With the probability of making a type I (a) and type II 
(0) error set at 0.05 and 0.20, respectively, and consider­
ing that a reduction in assumed normal GBS transmis­
sion rate of 50% to 25% or less would be of clinical 
importance, we estimated that data from about 340 de­
liveries per group would be required for the study. A 
total of 1020 participating women were randomly 
assigned, when labor had clearly started, to one of three 
groups according to a predefined block (10:10:10) 
allocation scheme.
22. Intervention
As in our pilot study, we used a viscous gel to apply 
the chlorhexidine because it adheres well to the mucosa 
and is a good lubricant [20]. The active gel consisted of 
chlorhexidine digluconate (3.0 g), hydroxypropylme- 
thylcellulose 4000 centiPoise (20.0 g), 100 ml glycerol, 
natrium hydroxide to obtain a pH of 7.0, and water to 
a volume of 1000 ml. After mixing, the viscous aqueous 
solution was transferred into glass bottles and sterilized 
(20 min at 120°C). This product was transferred into 
disposable sterile syringes and stored at 4°C. The 
placebo gel had the same composition except for the 
chlorhexidine digluconate and it was handled identical­
ly. There were no visual differences between the syringes 
containing the different gels.
For the duration of the trial, all antiseptic solutions 
and lubricants for obstetric use were removed from the 
wards and, instead, sterilized placebo gel, perishable 24 
h after opening, was available in 100 ml glass bottles. 
When a woman was in active labor, the attending 
obstetrician applied 10 ml gel (brought at room temper­
ature) from the syringe attached to a 14 cm plastic 
catheter around the portio and into the fornices. This 
procedure was repeated after 10 h in case delivery had 
not yet occurred, For this purpose, all syringes were 
delivered in duplicate.
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2,3. Data collection
All parturients were cultured before the application o f  
any gel. Cotton tipped wooden swabs were used, 
moistened with Todd-Hewitt broth, with addition of 8% 
lecithin and 3% Tween 80 to inactivate any chlorhex- 
idine remnants absorbed in the swab [23]. An anorectal 
swab was first taken, after which a second swab was 
used to sample the posterior half or the introitus. Using 
a sterile speculum, a third swab was rotated 360° in the 
cervical os to obtain a cervical specimen. Ear, pharynx 
and umbilicus o f all neonates were cultured directly 
after birth.
All swabs were stored at 4"( ’ and inoculated within 24 
h in the same bacteriological laboratory, The following 
media were used to plate the swabs semiquantitatively:
5% defibrmated sheep blood agar (48 h at 36°C),
Gasman agar witli 10 units/ml bacitracin and 5% 
defibrmated rabbit blood (anaerobically, 48 h at 36°C)
and Sabouraud agar (72 h at 30 C). Sabouraud agar and Of the 1020 participating women, 522 were enrolled in
Casman agar were used to deteet yeasts and one hospital and 498 in the other. Thirty-nine were not 
Haemophilus injftwttztit*, respectively, the latter also evaluated because cultures were incomplete or lost, or 
being recognized as an important cause ol neonatal in- delivery took place before any gel could have been ap- 
fections [24]. After plating, the swabs were put in a sc- plicated. Of the 981 analyzed mother-infant pairs, 327
were assigned to the chlorhexidine group, 328 to the
blems, results o f  additional cultures and antibiotic ther­
apy. Neonatal septicemia, meningitis and pneumonia 
were diagnosed from positive cultures o f blood, 
cerebrospinal fluid or tracheal aspirate, respectively. 
Probable infection’ was based on clinical suspicion with 
negative cultures. Follow up was continued until 3 
months and all women and their family doctors received 
a questionnaire for this purpose. In cases of twins, data 
on the first-born were processed only. Any spontaneous­
ly reported complaints were recorded.
2.4. Statistics
The Kruskal-Wallis test, Fisher’s exact test, logistic 
regression analysis and repeated measurement analysis 
of categorical data [25] were used for statistical analyses.
3, Results
m
Table i
Characteristics of enrolled parturients by group assignment
lective enrichment broth consisting of Todd-Hewitt
broth with 15/tg nalidixic acid per ml and 8/tg gen- placebo group and 326 to the control group. In total, 19 
tamicin per ml. After overnight incubation at 36°C, the (1.9%) twin pregnancies and 41 (4.2%) premature deliv- 
swabs were plated on blood agar and incubated at 36°C eries were enrolled. Table 1 summarizes a number o f  
for another 24 h, The growth density of microorganisms characteristics o f the three groups; no significant differ- 
(1,2, 3 or 4), expressed as growth in the corresponding 
streak area, on the directly plated agar plates was deter­
mined. Growth density 0 was scored if GBS were only 
isolated from the enrichment broth (or if only 1-2 col
onies of other species were grown on blood agar). The 
identification o f GBS was confirmed by a positive 
CAMP-reaction, abscnec o f a zone of inhibition around 
a bacitracin disc (0.04 units) on Casman blood agar 
(18-24 h at 36,’( ‘), and a group B latex agglutination test 
(Streptex, Wellcome Diagnostics).
Standard forms were used to record the data of moth­
er and child. Prenatal data included information on age, 
ethnic origin, obstetric history, assessment of gestational 
age, use of drugs, alcohol and nicotine, any loss of 
blood, toeolysis, anemia and diabetes mellitus or gesta­
tional diabetes.
In addition to the usual parameters of labor and deliv­
ery, data also included time of rupture of membranes, 
admission to the delivery ward and application(s) of gel.
Moreover, the following data were recorded: cervical 
dilatation at the moment o f application of gel, number 
of vaginal examinations, use of internal monitoring, 
fetal blood sampling and infection parameters. Initial 
infant data were collected and whether the infant receiv­
ed intensive, special or regular care.
Women and infants were followed up during their 
hospital stay with special attention to infectious pro-
Characteristic* Chlorhexidine Placebo Control
(n a  327) (n = 328) (« = 326)
Age (years)* mean (SD) 30.1 (4.6) 30.1 (4.5) 30,3 (4.6)
Pregnancy, median (range) 2 (1-7) 2 (1-8) 2 (1-11)
Parity, median (range) 1 (0-5) 1 (1-6) 1 (1-9)
Gestational age (days)
Mean (SD) 278 (11) 279 (11) 278 (U )
P5; P95 260; 295 260; 295 259; 295
Ethnic origin (% non- 6.7 7.9 7.1
Caucasian)
Growth density (%):
0: anorcctum/introitus/ 3.1/3,4/3.1 6.1/4.0/2.7 4.6/2,8/4.9
cervix
1-2: anorectum/ 3.4/S.8/4.9 6.4/6.7/5.2 3.1/3.7/3.4
introitus/cervix
3 -4 “: anorectum/ 10.4/5.2/3.7 7.0/4.9/2.7 7.7/6.1/3.7
introitus/cervix
Number of GBS carriers 63 (19.3) 70 (21.3) 57 (17.5)
(%)
35 (61.4)Heavily colonized (% of 40 (63.5) 33 (47.1)
GBS carriers)
*No significant differences between the three groups; means and 
medians tested with the Kruskal-Wallis test; percentages tested with 
two tailed Fisher’s exact test; growth densities tested for each culture 
site, “heavy colonization.
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Table 2
Pregnancy characteristics by intrapartum GBS carrier state
Characteristic Carriers 
(n = 190)
Non-carriers 
(n = 791)
P*
Obstetric history
& 1 immature/premature 7.9 12.1 NS
delivery (%)
& 1 intra-uterine death (%) 1.0 1.5 NS
2:1 perinatal mortality (%) 0.0 1.0 NS
Gestational age (days)
Mean (SD) 279 (11) 278 (11) NS
P5; P95 262; 294 259; 295
Prolonged (> 24  h) rupture of 13.2 11.5 NS
membranes (%)
Insulin dependent diabetes 2.1 0.5 0.05
mellitus (%) 19
Gestational diabetes (%; diet 4.7 2.9 NS
and/or insulin)
Vaginal bleeding after 20 2.6 4.6 NS
gestational weeks (%)
Anemia (% Hb < 6 .8  mmol/1) 15.8 22.6 0.04
Use of alcohol (%) 3.2 3.2 NS
Nicotin (%) 22.1 26.4 NS
Drugs (%) 0.5 0.1 NS
Use of corticosteroids (%) 0.0 0.5 NS
Tocolytic therapy (%; oral 3.2 2.5 NS
and/or intravenous)
^Percentages tested with two tailed Fisher’s exact test; means tested 
with the Kruskal-Wallis test; NS; not significant.
ences were found. Overall, GBS carriership was 
established in 190 (19,4%) of 981 women, 108 (56.8%) of 
the carriers being heavily colonized (growth density 3 or 
4). Anorectal, introital and cervical colonization was 
found in 169 (88.9%), 139 (73.2%) and 112 (58.9%) of 
carriers, respectively; the differences being statistically 
significant (P <  0.001 [25]). Genitals plus anorectum 
were colonized in 67.9%, only the genitals in 11.1% and 
just the anorectum in 21.1% o f the carriers.
Pregnancy characteristics o f intrapartum GBS car­
riers were compared to that o f non-carriers (Table 2). 
No differences in obstetric histories were found, nor in 
the use of tocolytic therapy during pregnancy or in ges­
tational age at delivery. More insulin-dependent 
diabetes mellitus was found in the GBS carrier group 
(two-tailed Fisher’s exact test, P  = 0.05), while non­
carriers suffered from anemia more often (two-tailed 
Fisher’s exact test, P  = 0.04).
Group assignment o f GBS carriers did not significant­
ly influence the clinical characteristics of deliveries and 
infants at birth (Table 3). In 98.4% of the chlorhexidine- 
group-assigned GBS carriers, the gel was applicated 
more than 30 min before birth. A second gel application 
was given to 5.8% of the total chlorhexidine group and 
4.9% of the placebo group. Gel was administered after 
the membranes had ruptured in 70.0% of GBS carriers.
Table 3
Characteristics of deliveries and infants of intrapartum GBS carriers by group assignment
Characteristic* Chlorhexidine
(n = 63)
Placebo
(n = 70)
Control 
(n = 57)
Delivery
Time 1st gel -* birth (min), median (P5; P95) 258 (42; 844) 207 (32; 830) ---
>30 min (%) 98.4 95.7 ---
Time ROMa — birth (h), median (P5; P95) 7.2 (0.9; 30.1) 7.2 (0.3; 35.6) 7.1 (0.5; 39.8)
2nd Stage of labor (min), median (P5; P95) 33 (4; 107) 32 (5; 100) 24(4; 110)
ROM* before 1st gel application (%) 71.4 68.6 ---
Maternal temperature 38°C (%) 3.2 1.4 3.5
Maternal leucocytosis > 1 6 x 1 09/l (%) 9.5 5.7 5.3
Foul smelling amniotic fluid (%) 1.6 2.9 0.0
Fetal tachycardia >160 beats/min (%) 3.2 7.1 3.5
No. of vaginal examinations, mean (SD) 5.6 (1.8) 5.2 (2.5) 5.1 (2.1)
Internal monitoring (%) 96.8 94.3 86.0
Fetal blood sampling (%) 4.8 2.9 8.8
Fetal distress (%) 3.2 8.6 8.8
Instrumental delivery (%) 23.8 22.9 21.1
Infant
Sex (% male) 50.8 40.0 50.9
Birthweight (g), mean (SD) 3340 (520) 3350 (470) 3310 (560)
5 min Apgar score, mean (SD) 9.6 (0.9) 9.4 (1.0) 9.4 (0.9)
pH of umbilical artery, mean (SD) 7.23 (0.08) 7.23 (0.08) 7.22 (0.08)
Pediatric involvement (%) 63.5 67.1 70.2
Admission to neonatal care unit (%)*
Intensive 1.6 0.0 0.0
Special 7.9 0.0 10.5
Regular 90.5 100.0 89.5
*No significant differences between the three groups, except for the % of neonates admitted to the (special) neonatal care unit (P = 0,012); means 
and medians tested with the Kruskal-Wallis test; percentages tested with two tailed Fisher’s exact test. aRupture of membranes.
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Table 4
Vertical transmission rates o f frequent perinatal pathogens and cor­
responding semiquantitative sumscore of growth densities for infants 
by group assignment
Pathogen Chlorhex- Placebo Control P* 
idine
Streptococcus agalactiae
na
Transmission (%) 
Sumscoreb: median 
P5; P95
Escherichia coli 
«a
Transmission (%) 
Sumscoreb: median 
P5; P95
Staphylococcus aureus
63
52.4
1
0; 13
226
36.3
0
0;6
na
Transmission (%) 
Sumscoreb: median
P5; P95
Candida albicans
na
Transmission 
Sumscoreb: median
P5; P95
21
42.9 
0
0; 6
61
27.9 
0
0; 4
70 
71.4 
2
0; 15
236
38.6
0
0;7
29
62.1
3
0; 12
71
31.0
0
0; 4
57
66.7 
2
0; 14
231
32.0 
0 
0;6
30
56.7 
2
0; 13
64
39.1 
0
0; 5
0.069
> 0.10
> 0.10
> 0.10
> 0.10
> 0.10
> 0.10
> 0.10
♦Percentages tested with two tailed Fisher’s exact test; medians tested 
with the Kruskal-Wallis test.
“Cases with positive neonatal culture(s) while negative maternal cul­
turéis) for concerning pathogen are excluded. 
hTotal score (growth density + 1) of ear, pharynx, and umbilicus 
(range 0-15).
The median interval between admission and the first 
application o f gel was 3.5 h for both gel-treated groups. 
The median cervical dilatation at the first application of 
gel was 4 cm. N o significant differences in infection par­
ameters were detected between the three groups of GBS 
colonized parturients. Group assignment had no influ­
ence on the condition of infants born of GBS carriers, 
although significantly more infants from both the 
Chlorhexidine and control group were admitted to the 
special care unit, as compared to the neonates from the 
placebo group (two-tailed Fisher’s exact test,
P = 0.012).
The vertical transmission rate of S. agalactiae was 
lower in the Chlorhexidine group, but the difference did 
not reach significance (two-tailed Fisher’s exact test, 
P = 0.069; Table 4). When testing the transmission rate 
for the chlorhexidine group (52.4%) versus that for the 
combined placebo plus control group (69.3%), the dif­
ference of 16.9% (95% confidence interval (Cl) 
2.2-31.6%) was significant (two-tailed Fisher’s exact 
test, P  = 0.026; one-tailed Fisher’s exact test, 
P = 0.017). These transmission rates resulted in 10.1%, 
15.2% and 11.7%) neonatal GBS colonization in the 
chlorhexidine, placebo and control group, respectively. 
Logistic regression analysis for the maternal carriers, 
with correction for the treatment group (no interac-
tions), reveals the introitus as the colonization site 
yielding the highest GBS vertical transmission rate 
(odds ratio 10.2; 95% Cl 4.3-24.5%).
No significant differences in transmission rates o f E, 
coli, S. aureus and C. albicans were found between the 
three groups (two-tailed Fisher’s exact test; Table 4). 
Overall, transmission rates of microorganisms declined 
in the following order: S . agalactiae (63.5%), S. aureus 
(53.9%), E. coli (35.6%) and C. albicans (32.7%). The 
degree of neonatal colonization with the various 
microorganisms, reflected by the sumscore of the 
growth densities for all three culture-sites, did not differ 
significantly among the three groups (Kruskal-Wallis 
test; Table 4). Haemophilus species (not associated with 
morbidity) were cultured from two women in the 
chlorhexidine group: H  influenzae type B only from one 
cervix and Haemophilus parainfluemae from the in­
troitus of both women. Only the ear of one symptom-
free neonate, bom of a non-colonized woman from the
i
control group, was colonized with H. influenzae (non 
type B). Microbial growth, which can be considered as 
a quality control of sample and culture techniques, was 
present in 95.1% of all maternal cultures (n = 2943) and 
in 90.5% of neonatal cultures from the placebo plus con­
trol groups (n = 1962).
Follow-up data until three months postpartum were 
obtained from all 981 mother-infant pairs. N o signifi­
cant differences between the three groups of GBS col­
onized mothers were detected, regarding the incidence 
of temperature >38°C, endometritis, wound infection 
(following perineal rupture, episiotomy, or caesarean 
section), antibiotic therapy and various other infectious 
complications. Similarly, there were no significant dif­
ferences between the control groups of GBS carriers and 
non-carriers (n = 269). No cases of endometritis or 
wound infection were registered among GBS carriers. 
Among the non-carriers (n = 791), four suffered from 
endometritis and two from infected wounds, caused by 
other pathogens than GBS.
There was no mortality among the infants born o f  
GBS carriers. One male infant (3635 g at 295 gestational 
days), born of a heavily colonized GBS carrier from the 
chlorhexidine group, suffered from early onset GBS sep­
sis and was discharged after successful treatment with 
ampicillin and gentamicin. The membranes had rup­
tured 3 h before the application of gel and some signs of 
infection were present during labor. Another boy, whose 
mother was heavily colonized with E. coli but not with 
GBS and was treated with placebo gel, suffered from 
pneumonia (E. coli and S . aureus) and was also suc­
cessfully treated with ampicillin and gentamicin without 
further sequelae.
Two children bom of non-carriers died: a small-for- 
gestational-age term boy at age 3 months died from cot 
death and a girl died within the first week due to 
transposition of the great vessels.
There were no significant differences regarding the in-
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cidence of ‘probable infection\ antibiotic therapy and 
duration of hospital stay for various neonatal reasons 
between the three groups o f infants born of GBS car­
riers. The same was true for the infants born o f mothers 
from the control groups o f carriers and non-carriers.
No adverse effects o f chlorhexidine or placebo gel 
were reported or observed.
4. Discussion
Colonization rates for the anorectum, introitus and 
cervix support the concept that the lower 
gastrointestinal tract is the principal reservoir for GBS. 
The introitus seems the most suitable site for screening, 
in view of the high GBS vertical transmission rate and 
relatively high GBS isolation rate at this location.
Maternal diabetes was identified as a risk factor for 
GBS colonization, as earlier reported by Baker [26].
In contrast to our pilot study [20], a modest reduction 
in vertical transmission rate o f 5. agalactiae by 
chlorhexidine gel was found in the present, first rando­
mized, study. In the non-randomized pilot study, how­
ever, the vagina was cleaned with saline before the 
application of the 0.3% chlorhexidine gel and only the 
cervix and anus of parturients were cultured. Moreover, 
0.01% benzalkoniumchloride was added to the gel as a 
preservative; any extra disinfecting effect, although 
unlikely in view of the high chlorhexidine concentration, 
not being excluded.
In 1992, the Swedish Chlorhexidine Study Group con­
cluded that intravaginal chlorhexidine flushing during 
labor reduced morbidity among full-term newborn in­
fants compared to placebo treatment with saline [22]. 
Parturients were cultured from the posterior fornix for 
GBS only. The infants were not cultured to assess the 
vertical transmission rate o f GBS. The excess morbidity 
among the infants born of GBS carriers was only 
statistically significant when respiratory disorder and 
(probable) infection were taken together, while infection 
alone did not reach significance. Culture-proven sep­
ticemia/meningitis occurred in one infant of both groups 
of GBS carriers. Parturients delivering prematurely were 
not included, nor was a second control group receiving 
no treatment at all to assess the impact o f flushing the 
vagina with saline.
It is known that chlorhexidine kills 99% of vaginal 
bacteria within 5 min [18]. In 98.4% of parturients, 
chlorhexidine gel was applicated more than 30 min 
before birth, while the median interval was 4.3 h. Al­
though no experimental data for chlorhexidine are avail­
able yet, the use o f a gel as a vehiculum may have 
advantages over an aqueous solution such as a longer 
duration of action, as is the case for povidone-iodine gel 
[27]. Activity o f chlorhexidine is reduced in the presence 
of serum, blood, pus and other organic matter [17]. This 
problem can be overcome by using a sufficiently high
concentration [18]. The chlorhexidine concentration 
used in our study was 600 times or more the minimal 
bactericidal concentration for GBS [28] and at least as 
high as in other clinical studies [19,20,22].
Preferably, chlorhexidine is applicated before rupture 
of the membranes, as the risk for ascending colonization 
and infection of the genital tract increases substantially 
after membrane rupture. The prevalence of positive gen­
ital cultures for GBS is significantly lower immediately 
after rupture of the membranes [29]. This may be due to 
a ‘wash out5 effect and/or inherent bacteriostatic proper­
ties of amniotic fluid [30]. The duration of this effect is 
not known. Reduction of vaginal pathogens by 
chlorhexidine and thereupon amniorrhexis would seem 
most beneficial. In the present study, the chlorhexidine 
gel was given in only 30% of GBS carriers before the 
membranes ruptured. In these cases, transmission oc­
curred in 44%; transmission occurred in 56% when gel 
was applicated after the membranes ruptured. For the 
placebo group, these percentages were 77% and 69%, 
respectively.
The effect of chlorhexidine might be increased by 
earlier application, preferably before membrane rup­
ture, and possibly by increasing the concentration 
and/or quantity. Randomizing patients during preg­
nancy instead of during labor could probably have gain­
ed time in this trial. Earlier application in routine use is 
possible because there is no need for the time-consuming 
process of enrolling, randomizing and culturing of a 
trial.
We conclude that vaginal disinfection with 0.3% 
chlorhexidine gel during labor modestly reduces vertical 
transmission of GBS. This raises the question of 
whether this reduction is of sufficient clinical impor­
tance to implement chlorhexidine disinfection in clinical 
practice. We theorize that the qualitative and quantita­
tive reduction in vertical transmission in the 
Netherlands (195 000 deliveries/year) may subsequently 
lead to a reduction by 4-62 cases of an estimated annual 
195 cases of early onset GBS sepsis. The costs of imple­
mentation can roughly be calculated analogous to The 
costs of a comparable product as catheter lubricant. 
This is manufactured at an industrial scale and purchas­
ed at prices of about Dfl. 2.50 per ready to use unit. The 
price of such products is mainly dependent on the costs 
of manufacturing and the applicator tip, whereas the in­
gredients contribute less than 5% to the final costs. The 
use of 250 000 packages/year would cost Dfl. 0,63 
million. The financial benefit would result from fewer 
admissions to neonatal intensive care units (average Dfl. 
30 000/neonate) and less handicapped children (up to 
Dfl. 2 million/lifetime). Assuming that early onset GBS 
sepsis will leave 1 out o f 8 neonates severely handicap­
ped, the total benefit would range between Dfl. 
1,12-17.36 million/year. Because the method is cost- 
effective, simple and safe, it should be considered for
A.H. Adriaanse el at./European Journal o f Obstetrics and Gynecology and Reproductive Biology 61 (1995) 135-141
routine use, not as a panacea but as a contribution to the 
prevention o f GBS infections in newborns.
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